{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:35:59Z","timestamp":1794724559374,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A\u03b242\/A\u03b240 ratios in cerebrospinal fluid (CSF) and blood are reduced in preclinical Alzheimer\u2019s disease (AD), but their temporal and correlative relationship with cerebral A\u03b2 pathology at this early disease stage is not well understood. In the present study, we aim to investigate such relationships using <jats:italic>App<\/jats:italic> knock-in mouse models of preclinical AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CSF, serum, and brain tissue were collected from 3- to 18-month-old <jats:italic>App<\/jats:italic><jats:sup>NL\u2212F\/NL\u2212F<\/jats:sup> knock-in mice (<jats:italic>n<\/jats:italic>\u2009=\u200948) and 2\u201318-month-old <jats:italic>App<\/jats:italic><jats:sup>NL\/NL<\/jats:sup> knock-in mice (<jats:italic>n<\/jats:italic>\u2009=\u200935). The concentrations of A\u03b242 and A\u03b240 in CSF and serum were measured using Single molecule array (Simoa) immunoassays. Cerebral A\u03b2 plaque burden was assessed in brain tissue sections by immunohistochemistry and thioflavin S staining. Furthermore, the concentrations of A\u03b242 in soluble and insoluble fractions prepared from cortical tissue homogenates were measured using an electrochemiluminescence immunoassay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In <jats:italic>App<\/jats:italic><jats:sup>NL\u2212F\/NL\u2212F<\/jats:sup> knock-in mice, A\u03b242\/A\u03b240 ratios in CSF and serum were significantly reduced from 12 and 16\u00a0months of age, respectively. The initial reduction of these biomarkers coincided with cerebral A\u03b2 pathology, in which a more widespread A\u03b2 plaque burden and increased levels of A\u03b242 in the brain were observed from approximately 12\u00a0months of age. Accordingly, in the whole study population, A\u03b242\/A\u03b240 ratios in CSF and serum showed a negative hyperbolic association with cerebral A\u03b2 plaque burden as well as the levels of both soluble and insoluble A\u03b242 in the brain. These associations tended to be stronger for the measures in CSF compared with serum. In contrast, no alterations in the investigated fluid biomarkers or apparent cerebral A\u03b2 plaque pathology were found in <jats:italic>App<\/jats:italic><jats:sup>NL\/NL<\/jats:sup> knock-in mice during the observation time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest a temporal sequence of events in <jats:italic>App<\/jats:italic><jats:sup>NL\u2212F\/NL\u2212F<\/jats:sup> knock-in mice, in which initial deposition of A\u03b2 aggregates in the brain is followed by a decline of the A\u03b242\/A\u03b240 ratio in CSF and serum once the cerebral A\u03b2 pathology becomes significant. Our results also indicate that the investigated biomarkers were somewhat more strongly associated with measures of cerebral A\u03b2 pathology when assessed in CSF compared with serum.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-023-01196-8","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T03:02:59Z","timestamp":1679713379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cerebral A\u03b2 deposition precedes reduced cerebrospinal fluid and serum A\u03b242\/A\u03b240 ratios in the AppNL\u2212F\/NL\u2212F knock-in mouse model of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Emelie","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi C.","family":"Saido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar K.","family":"Gouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"issue":"1","key":"1196_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):32.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1196_CR2","doi-asserted-by":"publisher","first-page":"a006270","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2(5):a006270.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"26","key":"1196_CR3","doi-asserted-by":"publisher","first-page":"9384","DOI":"10.1073\/pnas.1401564111","volume":"111","author":"G Meisl","year":"2014","unstructured":"Meisl G, Yang X, Hellstrand E, Frohm B, Kirkegaard JB, Cohen SI, et al. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Abeta40 and Abeta42 peptides. Proc Natl Acad Sci U S A. 2014;111(26):9384\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1196_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13(1):45\u201353.","journal-title":"Neuron"},{"issue":"6","key":"1196_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"7","key":"1196_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1196_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"issue":"4","key":"1196_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.dadm.2015.09.002","volume":"1","author":"E Stomrud","year":"2015","unstructured":"Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O. Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer\u2019s disease: a prospective 9-year study. Alzheimers Dement (Amst). 2015;1(4):403\u201311.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"1196_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1196_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-020-00595-5","volume":"12","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, Ward L, Burnham SC, Villemagne VL, Li QX, Collins S, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther. 2020;12(1):36.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1196_CR11","first-page":"e12097","volume":"12","author":"A Keshavan","year":"2020","unstructured":"Keshavan A, Wellington H, Chen Z, Khatun A, Chapman M, Hart M, et al. Concordance of CSF measures of Alzheimer\u2019s pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays. Alzheimers Dement (Amst). 2020;12(1):e12097.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"1196_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid Abeta42\/40 corresponds better than Abeta42 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55(2):813\u201322.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1196_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer\u2019s disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(5):316\u201320.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"1196_CR14","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14(1):e14408.","journal-title":"EMBO Mol Med"},{"key":"1196_CR15","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep"},{"issue":"7691","key":"1196_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"17","key":"1196_CR17","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","journal-title":"Neurology"},{"issue":"9","key":"1196_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019;76(9):1060\u20139.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1196_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"key":"1196_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid beta 42\/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179\u201387.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"Suppl 1","key":"1196_CR21","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med. 2022;63(Suppl 1):13S-S19.","journal-title":"J Nucl Med"},{"key":"1196_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","volume":"13","author":"SW Seo","year":"2017","unstructured":"Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, et al. Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017;13:130\u20137.","journal-title":"Neuroimage Clin"},{"issue":"3","key":"1196_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1212\/WNL.0b013e31825fdf18","volume":"79","author":"M Scholl","year":"2012","unstructured":"Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79(3):229\u201336.","journal-title":"Neurology"},{"issue":"194","key":"1196_CR24","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5(194):194re2.","journal-title":"Sci Transl Med."},{"issue":"7","key":"1196_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.15252\/emmm.201505026","volume":"7","author":"LF Maia","year":"2015","unstructured":"Maia LF, Kaeser SA, Reichwald J, Lambert M, Obermuller U, Schelle J, et al. Increased CSF Abeta during the very early phase of cerebral Abeta deposition in mouse models. EMBO Mol Med. 2015;7(7):895\u2013903.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"1196_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2001;21(2):372\u201381.","journal-title":"J Neurosci"},{"issue":"17","key":"1196_CR27","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J. 2017;36(17):2473\u201387.","journal-title":"EMBO J"},{"issue":"5","key":"1196_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci. 2014;17(5):661\u20133.","journal-title":"Nat Neurosci"},{"key":"1196_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nlm.2016.07.001","volume":"135","author":"A Masuda","year":"2016","unstructured":"Masuda A, Kobayashi Y, Kogo N, Saito T, Saido TC, Itohara S. Cognitive deficits in single App knock-in mouse models. Neurobiol Learn Mem. 2016;135:73\u201382.","journal-title":"Neurobiol Learn Mem"},{"issue":"5955","key":"1196_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1126\/science.1180962","volume":"326","author":"JE Kang","year":"2009","unstructured":"Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005\u20137.","journal-title":"Science"},{"key":"1196_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neurobiolaging.2020.07.018","volume":"95","author":"E Andersson","year":"2020","unstructured":"Andersson E, Janelidze S, Lampinen B, Nilsson M, Leuzy A, Stomrud E, et al. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer\u2019s disease. Neurobiol Aging. 2020;95:143\u201353.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1196_CR32","first-page":"172","volume":"111","author":"X Meng","year":"1992","unstructured":"Meng X, Rubin D, Rosenthal R. Comparing correlated correlation coefficients. Quantitative Methods Psychol. 1992;111(1):172\u20135.","journal-title":"Quantitative Methods Psychol"},{"key":"1196_CR33","doi-asserted-by":"crossref","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14(11):639\u201352.","DOI":"10.1038\/s41582-018-0079-7"},{"issue":"6","key":"1196_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ana.24270","volume":"76","author":"KF Roberts","year":"2014","unstructured":"Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, et al. Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol. 2014;76(6):837\u201344.","journal-title":"Ann Neurol"},{"issue":"11","key":"1196_CR35","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allue JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-beta 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1196_CR36","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, Ossenkoppele R, Jonsson M, Seeley W, et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2022;98(11):e1137\u201350.","journal-title":"Neurology"},{"issue":"12","key":"1196_CR37","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791\u2013800.","journal-title":"Neurology"},{"issue":"4","key":"1196_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simren J, Lantero-Rodriguez J, et al. Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143(4):487\u2013503.","journal-title":"Acta Neuropathol"},{"issue":"Pt 4","key":"1196_CR39","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O, Alzheimer\u2019s Disease Neuroimaging I. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139(Pt 4):1226\u201336.","journal-title":"Brain"},{"issue":"8\u20139","key":"1196_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med. 2009;1(8\u20139):371\u201380.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1196_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122\u201331.","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"1196_CR42","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138(Pt 3):772\u201383.","journal-title":"Brain"},{"issue":"3","key":"1196_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512\u20139.","journal-title":"Ann Neurol"},{"issue":"6","key":"1196_CR44","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74(6):826\u201336.","journal-title":"Ann Neurol"},{"issue":"11","key":"1196_CR45","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470\u201381.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1196_CR46","doi-asserted-by":"publisher","first-page":"e6294","DOI":"10.1371\/journal.pone.0006294","volume":"4","author":"P Buchhave","year":"2009","unstructured":"Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer\u2019s disease. PLoS ONE. 2009;4(7):e6294.","journal-title":"PLoS ONE"},{"issue":"1","key":"1196_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1\u201342, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98\u2013106.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1196_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643\u201363.","journal-title":"J Intern Med"},{"key":"1196_CR49","doi-asserted-by":"publisher","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2022;1\u201312.\u00a0https:\/\/doi.org\/10.1002\/alz.12787.","DOI":"10.1002\/alz.12787"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01196-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T04:30:34Z","timestamp":1679718634000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01196-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,25]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experimental procedures were carried out in accordance with the Swedish animal research regulations and approved by the committee of animal research at Lund University (ethical permit number: 7482\/2017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2\u00a0years, he has received consultancy\/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens.HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}